Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
36 studies found for:    scFv
Show Display Options
Rank Status Study
1 Completed IMCgp100 in Advanced Unresectable Melanoma
Conditions: Melanoma;   Advanced Disease;   Unresectable
Intervention: Drug: IMCgp100 injection
2 Not yet recruiting Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   CLL/SLL;   Lymphomas Non-Hodgkin's B-Cell;   ALL, Adult;   ALL, Pediatric
Intervention: Biological: CAR-20/19-T
3 Unknown  Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Multiple Myeloma;   Acute Myeloid Leukaemia;   Myelodysplastic Syndrome
Intervention: Biological: Anti-LeY- scFv-CD28-ζ vector,.
4 Recruiting Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
Conditions: Malignant Melanoma;   Breast Cancer
Intervention: Biological: T cells modified with RNA anti -cMET CAR
5 Recruiting CART-BCMA Cells for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-BCMA
6 Completed Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Drug: IMCgp100
7 Active, not recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Conditions: Lymphoma;   Lymphoplasmacytic Lymphoma;   Waldenström Macroglobulinemia
Intervention: Biological: DNA Vaccine
8 Recruiting CD22 Redirected Autologous T Cells for ALL
Conditions: B Cell Leukemias;   B Cell Lymphomas
Intervention: Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
9 Recruiting Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Condition: Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Intervention: Biological: CART-19
10 Recruiting CART19 in Patient With ALL
Condition: Leukemia, Acute Lymphoblastic
Intervention: Biological: CART 19
11 Recruiting Humanized CAR-T Therapy for Treatment of B Cell Malignancy
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Biological: CAR-T
12 Completed Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Biological: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha;   Drug: Placebo
13 Completed Ocular Biodistribution Study for Topically Applied ESBA105
Condition: Cataract
Intervention: Drug: Placebo
14 Recruiting Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
Condition: Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
Intervention:
15 Completed A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
Condition: Advanced Solid Tumours
Intervention: Drug: L19IL2
16 Active, not recruiting CART-19 for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-19 T cells
17 Recruiting CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphocytic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Genetic: Second generation CAR-T cells
18 Recruiting Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
Condition: Lymphoma, B-Cell
Intervention: Biological: CART20
19 Active, not recruiting CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Conditions: B Cell Lymphoma;   B Cell Leukemia
Intervention: Biological: Autologous 3rd generation CD19-targeting CAR T cells
20 Active, not recruiting CART-meso Long-term Follow-up
Condition: Subjects Who Have Received Lentiviral-based CART-meso Therapy
Intervention: Biological: lentiviral-based CART meso therapy

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.